secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001689548-26-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis reports Q4 net loss $88.9M; submits two NDAs; cash $926M
---------------------------------------------------------------

- Net loss $88.9M in Q4 2025 ($303.3M FY), vs $58.7M ($182.8M FY) prior year.
- Cash and investments $926.1M at Dec 31, 2025; plus $621.2M Jan 2026 offering funds operations into 2028.
- Submitted NDAs to FDA for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs).
- Topline results expected H1 2026 for vormatrigine Phase 3 (POWER1) and elsunersen EMBRAVE Part A.
- Board additions: Jeffrey Kindler, Stuart Arbuckle; promoted Sniecinski to COO, Petrou to President R&D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/0001689548-26-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000028/prax-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001689548-26-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer